All In Biotech

Drug Trial Radar · NCT06241313

Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine

Randomized, Double-blind, Placebo-Controlled, Multiple-Attack Study With an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerability, and the Consistency of Effect of Atogepant for the Acute Treatment of Migraine (ECLIPSE)

Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,158 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,158

Actual

Start

Mar 25, 2024

Primary completion

Jul 7, 2025

Study completion Aug 11, 2026

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Feb 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A migraine attack is a moderate or severe headache that usually occurs on one side of the head and is often accompanied by throbbing, sensitivity to light, sensitivity to sound, nausea, or other symptoms. The main goal of the study is to see if atogepant is effective, safe, and well-tolerated in treating migraine attacks quickly. Atogepant is a medicine currently approved for the preventive treatment of migraine in adults and has been shown to be effective and well tolerated when taken daily to prevent migraine attacks. This study includes double-blind phase means that neither the participants nor the study doctors know who is given which study treatment (atogepant or placebo) followed by an open-label phase meaning that both participants and study doctors know which study treatment is given. All participants will receive atogepant during the open-label part of the study. This study will include 1300 participants aged 18-75 years with a history of migraine at approximately 160 sites across the world. All participants will receive both atogepant and placebo to treat qualifying migraines. At the start of the study, participants will be randomized to 1 of 4 dosing sequences to determine when they will receive atogepant and when they will receive placebo during the study. After treating 4 qualifying migraine attacks, participants will receive open-label atogepant for any additional migraine attacks they have until the end of the study (Week 24). There may be a bigger responsibility for participants in this study than there would be in participants receiving standard of care treatment. participants will attend regular visits during the study at a hospital or clinic, as well as telephone visits, and the effects of treatment will be checked by completion of questionnaires in an electronic diary, medical assessments, blood tests, and checking for side effects.

Conditions

  • Migraine

Interventions

  • AtogepantDrug

    Oral Tablet

  • Placebo for AtogepantDrug

    Oral Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Pain Freedom at 2 Hours After the Double-Blind (DB) Dose for the First AttackTime frame: Approximately 16 Weeks

Locations

149 sites in 15 countries. Site status is shown where the registry gives one.

  • AZ Groeninge /ID# 257586

    Kortrijk, Belgium

  • CHR de la Citadelle /ID# 257587

    Liège, Belgium

  • H.-Hartziekenhuis Lier /ID# 257577

    Lier, Belgium

  • Universitair Ziekenhuis Antwerpen /ID# 257582

    Edegem, Antwerpen, Belgium

  • Universitair Ziekenhuis Brussel /ID# 257584

    Jette, Brussels Capital, Belgium

  • Cabinet Prive Dr Sava /ID# 257581

    Saint-Nicolas, Liege, Belgium

  • Jessa Ziekenhuis /ID# 257578

    Hasselt, Limburg, Belgium

  • Algemeen Ziekenhuis Sint-Jan Brugge /ID# 257585

    Bruges, West-Vlaanderen, Belgium

  • Baotou Central Hospital /ID# 258786

    Baotou, China

  • The first people's Hospital Affiliated to Shanghai Jiaotong University /ID# 259554

    Shanghai, China

  • The first affiliated hospital of bengbu medical college /ID# 258758

    Bengbu, Anhui, China

  • Beijing Friendship Hospital /ID# 258830

    Beijing, Beijing Municipality, China

  • Xuanwu Hospital Capital Medical University /ID# 258510

    Beijing, Beijing Municipality, China

  • Peking University Third Hospital /ID# 259573

    Beijing, Beijing Municipality, China

  • Chinese PLA General Hospital /ID# 257540

    Beijing, Beijing Municipality, China

  • Peking University First Hospital /ID# 258672

    Xicheng District, Beijing Municipality, China

  • Fujian Medical University Union Hospital /ID# 259575

    Fuzhou, Fujian, China

  • The First Affiliated Hospital of Xiamen University /ID# 259576

    Xiamen, Fujian, China

  • Lanzhou University Second Hospital /ID# 259667

    Lanzhou, Gansu, China

  • Guangzhou First People's Hospital /ID# 258656

    Guangzhou, Guangdong, China

  • The Second Affiliated Hospital of Guangzhou Medical University /ID# 258638

    Guangzhou, Guangdong, China

  • The University Of Hong Kong - Shenzhen Hospital /ID# 258462

    Shenzhen, Guangdong, China

  • The Affiliated Hospital of Guizhou Medical University /ID# 259536

    Guiyang, Guizhou, China

  • Hainan General Hospital /ID# 259548

    Haikou, Hainan, China

  • Hebei General Hospital /ID# 258583

    Shijiazhuang, Hebei, China

  • Zhengzhou People's Hospital /ID# 258670

    Zhengzhou, Henan, China

  • The Second Xiangya Hospital Of Central South University /ID# 260623

    Changsha, Hunan, China

  • The Third Xiangya Hospital of Central South University /ID# 258787

    Changsha, Hunan, China

  • Zhuzhou Central Hospital /ID# 260076

    Zhuzhou, Hunan, China

  • The Second Affiliated Hospital of Nanjing Medical University /ID# 258648

    Nanjing, Jiangsu, China

  • The Second Affiliated Hospital of Soochow University /ID# 259551

    Suzhou, Jiangsu, China

  • The First Affiliated Hospital of Soochow University /ID# 258783

    Suzhou, Jiangsu, China

  • Jiangxi Pingxiang Peoples Hospital /ID# 258652

    Pingxiang, Jiangxi, China

  • The First Hospital of Jilin University /ID# 259585

    Changchun, Jilin, China

  • The Second hospital of Jilin university /ID# 258556

    Changchun, Jilin, China

  • General Hospital of Northern Theater Command /ID# 259556

    Shenyang, Liaoning, China

  • Shaanxi Provincial PeopleS Hospital /ID# 259529

    Xi'an, Shaanxi, China

  • Second Hospital of Shanxi Medical University /ID# 259669

    Taiyuan, Shanxi, China

  • West China Hospital, Sichuan University /ID# 258664

    Chengdu, Sichuan, China

  • Tianjin Medical University General Hospital /ID# 259513

    Tianjin, Tianjin Municipality, China

Showing 40 of 149 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.